Arteaga R, Herranz J L, Armijo J A
Neuropediatrics Service, M. de Valdecilla Hospital, Faculty of Medicine, University of Cantabria, Santander, Spain.
Epilepsy Res. 1993 Jan;14(1):73-85. doi: 10.1016/0920-1211(93)90076-j.
The relationship between platelet GABA-transaminase (GABA-T) activity and either epilepsy or its treatment has been studied in 281 epileptic children: 55 were newly diagnosed untreated patients and 226 were chronically receiving anticonvulsants (154 in monotherapy and 72 in polytherapy). Results were compared with those from 48 control children. Untreated children had a GABA-T activity of 9.1 +/- 3.7 pmol/min/mg protein, lower than the control group (10.6 +/- 3.8 pmol/min/mg, P < 0.05), whereas treated epileptic children had higher values (11.9 +/- 6.3 pmol/min/mg) than those untreated (P < 0.01). In untreated children, the seven with absences and the nine with simple partial seizures had a GABA-T activity of 6.9 +/- 3.3 and 7.8 +/- 3.2 pmol/min/mg, respectively, lower than the control group (P < 0.05). In treated patients, those receiving valproate (VPA) in monotherapy had a GABA-T activity of 15.3 +/- 7.5 pmol/min/mg, higher than both the control group and the untreated children (P < 0.001). All patients receiving VPA in mono- or polytherapy had a higher activity than those receiving other anticonvulsants (16.4 +/- 8.4 vs. 9.9 +/- 3.9 pmol/min/mg, P < 0.001), the activity in Lennox syndrome and myoclonic epilepsies being significantly higher than in those with absences and partial epilepsy. GABA-T activity did not correlate with doses or trough steady-state serum levels of VPA. Platelet GABA-T could be useful as a peripheral marker of GABAergic alterations and GABAergic effects of antiepileptic drugs in epileptic patients.
对281例癫痫患儿的血小板γ-氨基丁酸转氨酶(GABA-T)活性与癫痫及其治疗之间的关系进行了研究:55例为新诊断的未治疗患者,226例为长期接受抗惊厥药物治疗的患者(154例接受单一疗法,72例接受联合疗法)。将结果与48例对照儿童的结果进行比较。未治疗儿童的GABA-T活性为9.1±3.7 pmol/分钟/毫克蛋白,低于对照组(10.6±3.8 pmol/分钟/毫克,P<0.05),而接受治疗的癫痫患儿的值(11.9±6.3 pmol/分钟/毫克)高于未治疗患儿(P<0.01)。在未治疗儿童中,7例失神发作患儿和9例单纯部分性发作患儿的GABA-T活性分别为6.9±3.3和7.8±3.2 pmol/分钟/毫克,低于对照组(P<0.05)。在接受治疗的患者中,接受丙戊酸(VPA)单一疗法的患者GABA-T活性为15.3±7.5 pmol/分钟/毫克,高于对照组和未治疗儿童(P<0.001)。所有接受VPA单一或联合疗法的患者的活性均高于接受其他抗惊厥药物的患者(16.4±8.4对9.9±3.9 pmol/分钟/毫克,P<0.001),Lennox综合征和肌阵挛性癫痫患者的活性显著高于失神发作和部分性癫痫患者。GABA-T活性与VPA的剂量或谷值稳态血清水平无关。血小板GABA-T可作为癫痫患者GABA能改变和抗癫痫药物GABA能作用的外周标志物。